


## (S)-Remoxipride hydrochloride

<b>Cat. No.:</b>	HY-101313A
<b>CAS No.:</b>	73220-03-8
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>24</sub> BrClN <sub>2</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	407.73
<b>Target:</b>	Dopamine Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(S)-Remoxipride ((-)-Remoxipride) hydrochloride is a selective dopamine D <sub>2</sub> -receptor antagonist with an IC <sub>50</sub> value of 1.57 μM. (S)-Remoxipride hydrochloride can be used for the research of psychotic disorder <sup>[1]</sup> .
<b>In Vitro</b>	(S)-Remoxipride hydrochloride (1-100 μM; 20 min) shows binding efficiency with IC <sub>50</sub> s of 100, 1.57 and 42 μM for dopamine D <sub>1</sub> , dopamine D <sub>2</sub> and α <sub>1</sub> -Adrenocceptor, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	(S)-Remoxipride hydrochloride (0.1-100 μM/kg; i.p. 60 min prior to apomorphine) blockades apomorphine-induced behaviors in rats and vomiting in dogs <sup>[1]</sup> . (S)-Remoxipride hydrochloride (0.1-10 mg/kg; i.p. 30 min prior to apomorphine) displaces [ <sup>3</sup> H]spiperone from both striatal and extra-striatal areas <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Ogren SO, et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA